Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).

OBJECTIVES:
The EuResist expert system is a novel data-driven online system for computing the probability of 8-week success for any given pair of HIV-1 genotype and combination antiretroviral therapy regimen plus optional patient information. The objective of this study was to compare the EuResist system vs. human experts (EVE) for the ability to predict response to treatment.
Ler mais

Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort

Autores: Abecasis AB, Assel M, Bartha I, Luca AD, Müller V, Paredes R, Rosi A, Schülter E, Sloot PMA, Sönner-borg A, Svärd J, Torti C, van de Vijver DC, Van Laethem K, Vandamme AM, Zazzi M
Ano de Publicação: 2013
Journal: BMC Infectious Diseases
Link: http://www.biomedcentral.com/1471-2334/13/537/

Superinfection with drug resistant HIV strains could potentially contribute to compromised therapy in patients initially infected with drug-sensitive virus and receiving antiretroviral therapy. To investigate the importance of this potential route to drug resistance, we developed a bioinformatics pipeline to detect superinfection from routinely collected genotyping data, and assessed whether superinfection contributed to increased drug resistance in a large European cohort of viremic, drug treated patients.
Ler mais

HIV-1 subtype is an independent predictor of reverse transcriptase mutation k65r in HIV-1 patients treated with combination antiretroviral therapy including tenofovir

Autores: Abecasis AB, Camacho RJ, Clotet B, De Luca A, Grossman Z, Schülter E, Snoeck J, Sönnerborg A, Struck D, Theys K, Torti C, Vandamme AM, Vercauteren J, Zazzi M
Journal: Antimicrobial Agents and Chemotherapy
Link: http://www.ncbi.nlm.nih.gov/pubmed/23183438

Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.
Ler mais

Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).

Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort

HIV-1 subtype is an independent predictor of reverse transcriptase mutation k65r in HIV-1 patients treated with combination antiretroviral therapy including tenofovir

About GHTM

Contacts

Subscribe Newsletter